{"schema_version":"secwatch.filing_event.v1","accession":"0001178670-25-000050","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.713112+00:00","generated_at":"2026-05-22T23:47:06.849216+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B","bullets":["Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.","Q1 global net product revenues $469M, 28% growth YoY; hATTR-PN franchise grew 36%.","AMVUTTRA (vutrisiran) received FDA approval for ATTR-CM; launch underway with early progress.","Qfitlia (fitusiran) approved by FDA for hemophilia A/B, sixth Alnylam-discovered RNAi therapeutic.","Reiterated FY2025 combined net product revenue guidance of $2.05B-$2.25B."],"urls":{"canonical":"https://secwatch.observer/filing/0001178670-25-000050","json":"https://secwatch.observer/filing/0001178670-25-000050.json","markdown":"https://secwatch.observer/filing/0001178670-25-000050.md","text":"https://secwatch.observer/filing/0001178670-25-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/0001178670-25-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/alny-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T23:47:06.849216+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}